HPV: Page 3

Todos gains U.S. lab, Videssa cancer tests via Provista deal
Provista has developed a line of protein-based blood tests for the early diagnosis of cancer. Its Videssa Breast blood test is commercially available for help in interpreting abnormal or difficult-to-interpret imaging findings. Tests based on the same technology are being developed for endometrial cancer, ovarian cancer, and cancers associated with HPV.
January 8, 2020
2020 01 09 22 46 7361 Business Deal Corporate 400
New HPV saliva test may speed detection of mouth, throat cancers
Investigators at Duke University, the University of California, Los Angeles (UCLA), and other institutions developed an acoustofluidic noninvasive technique that analyzes saliva for the presence of HPV type 16, the pathogenic strain that causes oropharyngeal cancers (OPCs). Their acoustofluidic platform detected OPC in the saliva of 80% of patients with cancer confirmed by tissue biopsies, reported co-lead investigator Tony Jun Huang, PhD, a professor of mechanical engineering and mechanical science at Duke, and colleagues.
December 17, 2019
2019 12 17 22 01 3945 Saliva Hpv Test Adj 20191217224828
Becton Dickinson files for Onclarity FDA approval in 11 more HPV types
The Onclarity test is currently approved for detecting the three HPV genotypes -- 16, 18, and 45 -- that cause most cases of cervical cancer and precancer. However, the test detects 14 high-risk forms of HPV, according to Becton Dickinson, and the PMA filing seeks approval for 11 additional types, including types 31, 51, and 52. In a statement, the company explained that while HPV types 16, 18, and 45 have traditionally caused most cases of cervical cancer, they are becoming less common due to HPV vaccination in younger populations.
November 13, 2019
2019 08 20 21 56 4986 Becton Aacc 2019 400
Older women miss out on cervical cancer screening
Practice guidelines suggest that between the ages of 30 and 65, women should undergo screening with an HPV test every five years or a Pap test every three years in consultation with their doctor.
November 10, 2019
2019 11 11 20 38 6245 Woman Patient Asian 400
What will it take for home cervical cancer testing to take off?
In a large U.S. study conducted by Kaiser Permanente Washington, women who were overdue for cervical cancer screening were sent home-testing kits for HPV, but only about 12% sent them back. And though the screening rate was improved, the rate of detection for precancerous lesions was not significantly higher. In addition, a sizeable percentage of those with the most worrisome findings failed to follow up with colposcopy as they should have, according to results published November 6 in JAMA Network Open. Nevertheless, researchers have cause for optimism.
November 7, 2019
2019 11 07 23 47 6944 Squamous Epithelial Cells Cervical 400
NeuMoDx adds HPV test with pathology spin-off Self-screen
October 16, 2019
2019 05 17 20 09 8391 Hpv 400
Most Popular
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Werfen completes $2B acquisition of Immucor, expands presence in specialized diagnostics
Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition
Test shows promise for improving HPV triage
The test combines multiplexed reverse transcription polymerase chain reaction (RT-PCR) technology for measuring RNA and next-generation sequencing for detecting high-risk strains of HPV. It was developed using Thermo Fisher Scientific's Ion AmpliSeq multiplexed PCR technology; the prototype study was funded by the Institut Pasteur in Paris.
August 11, 2019
2019 08 12 20 56 9511 Papillomavirus Particles 20190812200126
Qiagen liquid biopsy to guide Inovio immunotherapy
The test will be used to help predict which patients will benefit from receiving VGX-3100, a DNA-based immunotherapy in phase III development for the treatment of women positive for HPV types 16 and 18, which cause most cervical cancers and high-grade squamous intraepithelial lesions, the two companies said in a joint statement on May 16. Inovio plans to file a biologics license application (BLA) for the drug in the U.S. in 2021.
May 16, 2019
2019 05 17 20 14 3434 Uterus Cervix 400
Previous Page
Page 3 of 3